Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)
Year: 2023
Type: conference-abstract
Source: Blood
Authors: Tariq Kewan, Jan Philipp Bewersdorf, Ondrej Blaha, Maximilian Stahl, Najla H Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Maria L Amaya, Joshua F. Zeidner, Michael R. Savona, Jessica M. Stempel, Namrata Sonia Chandhok, Constantine Logothetis, Rahul Ramaswamy, Ameera Rose, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Rory M. Shallis, Zhuoer Xie, Eric Padron, Jaroslaw P. Maciejewski, David A Sallman, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan
Institutions: Yale Cancer Center, Yale University, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, Johns Hopkins University, University of Miami, Sylvester Comprehensive Cancer Center, Cleveland Clinic, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Roswell Park Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Colorado Anschutz, UNC Lineberger Comprehensive Cancer Center, Vanderbilt University Medical Center, Washington University in St. Louis, Brigham and Women's Hospital, Harvard University, IRCCS Humanitas Research Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389235083